Evidence hub

Multiple Sclerosis: cell-therapy evidence by therapy class

Across every stem-cell intervention, ClinicalTrials.gov holds 92 registered records for Multiple Sclerosis — 13 recruiting, 3 at Phase 3 or 4, in 31 countries. Snapshot 2026-08-29.

Medical review statusMedically reviewedReviewed by: Stem Plus medical teamReviewed on: 2026-08-29Last evidence update: 2026-08-29Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

The condition, and why cells are proposed

MS is immune-mediated demyelination with axonal loss. It holds an unusual position in this field: autologous haematopoietic transplantation has controlled evidence in aggressive relapsing disease and is offered in national health systems in several countries, while mesenchymal infusions marketed to MS patients have a much weaker base. The gap between those two is the single most important distinction in this indication.

Therapy classes side by side

Therapy classRegisteredRecruitingPhase 3/4Countries
MSC373019
HSCT386315
exosomes2002
PRP0000

Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.

Geography of the research

United States accounts for about 46% of country mentions among sampled studies; 31 countries host at least one site.

CountryStudies with a site there
United States31
Italy6
United Kingdom6
Spain5
Sweden5
Canada4
Jordan3
Trinidad and Tobago3

The largest registered studies

Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.

StudyPhaseStatusPlanned nLead sponsorStart
NCT06065852 — National Registry of Rare Kidney Diseasesn/aRecruiting35,000UK Kidney Association2009-11-06
NCT01953523 — Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditionsn/aCompleted3,000Elliot Lander2013-09-02
NCT02674217 — Outpatient Hematopoietic Grafting in Multiple Sclerosis Employing Autologous Peripheral Blood Stem Cellsn/aUnknown1,000Centro de Hematología y Medicina Interna2015-05
NCT02795052 — Neurologic Stem Cell Treatment Studyn/aRecruiting500MD Stem Cells2016-06
NCT02157064 — Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosisn/aUnknown221StemGenex2014-05
NCT05832515 — AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple SclerosisPhase 1Recruiting200St. Petersburg State Pavlov Medical University2020-10-01

Most recently registered

StudyPhaseStatusPlanned nLead sponsorStart
NCT06228781 — Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosisn/aNot Yet Recruitingn/aTianjin Medical University General Hospital2026-12-01
NCT07521384 — Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapyn/aEnrolling By Invitationn/aHealing Hope International2026-06-01
NCT07635693 — ATLG Levels in Autologous HSCT for Multiple Sclerosisn/aRecruitingn/aCiceri Fabio2026-05-04
NCT06841068 — Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosisn/aWithdrawnn/aWake Forest University Health Sciences2026-02
NCT06607900 — hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseasesn/aNot Yet Recruitingn/aXuanwu Hospital, Beijing2025-07-01

Reading this honestly

Registration counts measure activity, not effect. A study appears here the moment it is registered — before any participant is enrolled, and regardless of whether results are ever posted. For Multiple Sclerosis specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.

Frequently asked

How many stem-cell trials exist for Multiple Sclerosis?

92 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 13 were recruiting.

Which therapy class is furthest along for Multiple Sclerosis?

Ranked by Phase 3/4 records: HSCT (3), MSC (0), exosomes (0), PRP (0).

Does a recruiting trial mean I can be treated?

No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads

Download the query data

Download CSV · Download JSON

Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.